^
Association details:
| Biomarker: | MAP2K1 K59del |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
Excerpt:
...we tested whether the MEK mutations K59del and P387S found in the GSK2118436-resistant clones activate MEK and promote resistance to GSK2118436 and GSK1120212....expression of MEK1K59del and MEK1Q56P in A375 cells decreased the ability of GSK2118436 to inhibit proliferation...
DOI:
10.1158/1535-7163.MCT-11-0989
